SOURCE: OmniComm Systems, Inc.

April 02, 2007 07:00 ET

Cardium Therapeutics Chooses OmniComm Systems Inc. Over Competing EDC Vendors as Its Web-Based Data Collection and Management Solution

Forward-Focused Medical Technology Company Chooses OmniComm's Client Intuitive TrialMaster® EDC Solution for a Phase 3 Multi-Site Cardiovascular Therapeutic Study for Women

FT. LAUDERDALE, FL -- (MARKET WIRE) -- April 2, 2007 -- OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that Cardium Therapeutics of San Diego, CA has selected the TrialMaster EDC solution for conducting a Phase 3 study in women which will evaluate Generx™ (alferminogene tadenovec) as a potential treatment for myocardial ischemia (insufficient blood flow within the heart muscle).

Generx is considered the first and only DNA-based cardiovascular therapeutic to be advanced to Phase 3 and is believed to be the only current Phase 3 product candidate for stable angina, a chronic medical condition affecting millions of patients in the U.S. and worldwide. "During a clinical trial there can be significant challenges in getting trial data when you want it and in the format that you need it," said Anthony Andrasfay, Vice President of Clinical Operations for Cardium. "The TrialMaster EDC solution provides us with an intuitive and easy to use export tool that simplifies the process. Integration is also very important to us and with the TrialMaster solution we've been able to easily integrate with our IVRS solution to manage enrollment and randomization."

OmniComm's TrialMaster is an easy to use and flexible web-based EDC and trial management solution. Clients like Cardium can benefit from the feature-rich functionality inherent in TrialMaster. And they can conduct their clinical trials more effectively using software and services that optimize the efficiency and accuracy of data collection, while reducing the costs associated with paper-based clinical trials.

"It is a tribute to OmniComm's dedication to providing unmatched customer focused EDC solutions that Cardium has chosen TrialMaster for their data management needs," said Cornelis F. Wit, President and CEO of OmniComm. Our team is proud to be partnering with Cardium as they work to bring breakthrough products to the marketplace. Our TrialMaster solution provides companies such as Cardium with a flexible and cost effective solution to securely collect, validate, analyze and transmit clinical study data."

About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications. For more information about Cardium and its businesses, products and therapeutic candidates, please visit www.cardiumthx.com or view its brochure at http://www.cardiumthx.com/flash/pdf/CardiumTHX_Brochure.pdf and its filings with the Securities and Exchange Commission.

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. In a market overview titled "The Promise of Next-Gen eClinical Trial Software" by Forrester Research, OmniComm was given the highest rating among its competitors for industry middleware. OmniComm Systems Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Contact Information

  • CONTACT:
    Lizanne Kelley
    OmniComm Systems, Inc.
    954-473-1254 Extension 283
    Email Contact